Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e211-

  Van Putten, Maaike ^a   Young, Courtney ^a   Van Berg, Sjoerd Den ^a   Pronk, Amanda ^a   Hulsker, Margriet ^a   Karnaoukh, Tatyana G ^b   Vermue, Rick ^b   Van Dijk, Ko Willems ^a   De Kimpe, Sjef ^b   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa BV   (Netherlands)

Author keywords

Antisense oligonucleotides; Bioavailability; Duchenne muscular dystrophy; Dystrophin; Oral administration

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLYCEROL DIDECANOATE; ISIS 104838; SODIUM CAPRATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; ENCAPSULATION; HEART; INTESTINE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE DISTRIBUTION; TRICEPS BRACHII MUSCLE;

EID: 84925243783     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.62     Document Type: Article

References (23)

1. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
2. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
3. Havens, MA, Duelli, DM and Hastings, ML (2013). Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev RNA 4: 247-266.
4. Muntoni, F and Wood, MJ (2011). Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10: 621-637.
5. Kohler, M, Clarenbach, CF, Bahler, C, Brack, T, Russi, EW and Bloch, KE (2009). Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 80: 320-325.
6. Monaco, AP, Bertelson, CJ, Liechti-Gallati, S, Moser, H and Kunkel, LM (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
7. Emery, AE (2002). The muscular dystrophies. Lancet 359: 687-695.
8. Arora, V, Knapp, DC, Reddy, MT, Weller, DD and Iversen, PL (2002). Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 91: 1009-1018.
9. Geary, RS, Khatsenko, O, Bunker, K, Crooke, R, Moore, M, Burckin, T et al. (2001). Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 296: 898-904.
10. Raoof, AA, Chiu, P, Ramtoola, Z, Cumming, IK, Teng, C, Weinbach, SP et al. (2004). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 93: 1431-1439.
11. Tillman, LG, Geary, RS and Hardee, GE (2008). Oral delivery of antisense oligonucleotides in man. J Pharm Sci 97: 225-236.
12. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580.
13. Verhaart, IE, Tanganyika-de Winter, CL, Karnaoukh, TG, Kolfschoten, IG, de Kimpe, SJ, van Deutekom, JC et al. (2013). Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther 23: 228-237.
14. Betts, C, Saleh, AF, Arzumanov, AA, Hammond, SM, Godfrey, C, Coursindel, T et al. (2012). Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids 1: e38.
15. Mann, CJ, Honeyman, K, McClorey, G, Fletcher, S and Wilton, SD (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4: 644-654.
16. Jang, SF, Goins, BA, Phillips, WT, Santoyo, C, Rice-Ficht, A and McConville, JT (2013). Size discrimination in rat and mouse gastric emptying. Biopharm Drug Dispos 34: 107-124.
17. Raoof, AA, Ramtoola, Z, McKenna, B, Yu, RZ, Hardee, G and Geary, RS (2002). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 17: 131-138.
18. Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
19. Monteleone, G, Fantini, MC, Onali, S, Zorzi, F, Sancesario, G, Bernardini, S et al. (2012). Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 20: 870-876.
20. Falzarano, MS, Passarelli, C, Bassi, E, Fabris, M, Perrone, D, Sabatelli, P et al. (2013). Biodistribution and molecular studies on orally administered nanoparticle-AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice. Biomed Res Int 2013: 527418.
21. Heemskerk, HA, de Winter, CL, de Kimpe, SJ, van Kuik-Romeijn, P, Heuvelmans, N, Platenburg, GJ et al. (2009). In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
22. Maher, S, Leonard, TW, Jacobsen, J and Brayden, DJ (2009). Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliv Rev 61: 1427-1449.
23. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25.